Study of the efficacy and safety of dimethyloxobutylphosphonyldimethylate in complex therapy of patients with the consequences of ischemic stroke

According to the instructions, Dimethyloxobutylphosphonyldimethylate stabilizes cell membranes, restoring the reactivity of cerebral vessels, improving the functions of the large hemispheres and the brain stem. Aim. To assess the effectiveness and tolerability of the preparation Dimephosphone in com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Consilium medicum (Online) 2021, Vol.23 (2), p.127-130
Hauptverfasser: Belova, Yuliana A., Kotov, Sergey V.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:According to the instructions, Dimethyloxobutylphosphonyldimethylate stabilizes cell membranes, restoring the reactivity of cerebral vessels, improving the functions of the large hemispheres and the brain stem. Aim. To assess the effectiveness and tolerability of the preparation Dimephosphone in complex therapy in patients with the consequences of ischemic stroke, with chronic cerebrovascular insufficiency due to atherosclerosis and/or hypertension compared to traditional therapy in patients. Materials and methods. The study included patients of both sexes aged 35 to 80 years who had an ischemic stroke. The main criteria for clinical effectiveness were the assessment of cognitive functions by MoCA scales, FAB, Modified Strup Test. Secondary indicators confirming the effectiveness of therapy were the assessment of the dynamics of cytochemical study data (indicators of mitochondrial activity of enzymes in peripheral blood lymphocytes). Results. Dimephosphone had a positive impact on cognitive functions, improved indicators of flexibility/rigidity of control, automation of cognitive functions. Indicators of mitochondrial activity of enzymes require further study. Conclusion. Dimephosphone has proved to be an effective and well tolerated drug.
ISSN:2075-1753
2542-2170
DOI:10.26442/20751753.2021.2.200693